Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF), spoke about cooperation with the Swiss company Adienne Pharma & Biotech for the production of the Sputnik V coronavirus vaccine in Italy. He announced this in an interview with the Rai 3 TV channel, TASS reports.
According to Dmitriev, new jobs will appear thanks to the production mechanism. It is expected that the production of the Russian drug in Italy could begin in the summer, and by the end of 2021 the number of vaccines produced could reach 700 million doses.
Sputnik V became the world's first registered vaccine based on the human adenovirus. Currently, the development of Russian scientists is among the ten best vaccine candidates in the list of the World Health Organization (WHO). The vaccine has already been registered in Russia, Belarus, Argentina, Mexico, Bolivia, Serbia, Algeria, Armenia, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea and Tunisia.